/Investor DB

Oxford Bioscience Partners

Find your way into Oxford Bioscience Partners

Sign up to find every way you can get introduced to Oxford Bioscience Partners

  • Your email: who you already know at Oxford Bioscience Partners, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Oxford Bioscience Partners team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

✨ Fox Verdict
Sign up to see your fit
Tracked investments
5

What they invest in

from 5 of 5 portfolio companies

Biotech ×4Healthtech ×4Medical Devices ×2Digital Health ×1Hardware ×1

HQs:United States×4

Investments · 5 tracked

founders shown can be your intro path
Cambridge Endoscopic Devicesin

BiotechFramingham, US

Woojin Lee(Executive Officer, Director)inJohn Schulte(Executive Officer, Director)

BoardGlen Kashuba(Director)inHoward Donnelly(Director)Jeff Barnes(Director)

Co-investorsBoston Harbor Angels

CardioFocuscardiofocus.comin𝕏Feb 2011 · $30.6M

CardioFocus develops Pulsed Field Ablation (PFA) technologies and systems for electrophysiologists to treat complex cardiac arrhythmias with precision and control.

BiotechHealthtechMedical DevicesMarlborough, US

Lauren Jennings(Executive Officer)Warren Clark(Executive Officer)Stephen Sagon(Executive Officer, Director)inAnjie Roldan(Executive Officer)inWarren R. Clark III(Executive Officer)Stephan S. Ogilvie(CEO)in

Co-investorsBioBritSaints CapitalSV Health InvestorsAccuitive Medical VenturesSV Life Sciences

Dicerna Pharmaceuticalsdicerna.com𝕏

A pharmaceutical company developing treatments for serious chronic diseases with a focus on long-term health solutions and improving medicine access and affordability globally.

BiotechDigital HealthHealthtech

Co-investorsAccess BiotechnologyBain Capital Life SciencesRidgeback CapitalRA Capital

Hydrocisionhydrocision.comin𝕏

HydroCision develops minimally invasive surgical instruments using proprietary FluidJet technology to selectively remove soft tissue in a precise manner.

BiotechHardwareHealthtechMedical DevicesNorth Billerica, US

PAUL KOWALSKI(Executive Officer)inRICHARD A. LYTLE, III(Executive Officer, Director)THOMAS D. ABERT(Executive Officer)inPATRICIA VANBLARCOM(Executive Officer)Rick Lytle(President & Chief Executive Officer)in

BoardLONG ZHAN(Director)

Co-investorsBioVenturesNewbury Ventures

Mitralignmitralign.com

HealthtechTewksbury, US

Lisa Mastromattei(Executive Officer)Lisa Wipperman Heine(Executive Officer)Sophia Wong(Executive Officer)Richard P. Geoffrion(Executive Officer, Director)

BoardMartien Van Osch(Director)Daniel Cole(Director)

Co-investors415 CapitalQiming Venture PartnersSaints CapitalXeraya CapitalForbion

Fund performance · per public LP disclosures · 4

as of Jun 2020
FundVintageCommittedNet IRRTVPIDPI
Oxford Bioscience Partners IVLPs: The Regents of the University of California2001—-6.6%0.71x0.71x
Oxford Bioscience Partners IV, L.PLPs: The Regents of the University of California2001—-6.6%0.71x0.71x
Oxford Bioscience Partners IIILPs: The Regents of the University of California1999—-13.4%0.38x0.38x
Oxford Bioscience Partners III, L.PLPs: The Regents of the University of California1999—-13.4%0.38x0.38x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Frequently asked questions

How many investments has Oxford Bioscience Partners made?
Oxford Bioscience Partners has 5 tracked investments.